drugset
drugset / Trial / NCT02210494

Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)

NCT02210494 ↗

Phase 1 Unknown 5 enrolled Effexus Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the safety of Secretrol® in patients undergoing endoscopic mucosal resection for early adenocarcinoma of the esophagus.

Timeline

Start
2013-04
Primary completion
2015-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Secretrol Unknown — —

Indications

ulcer disease